OverviewSuggest Edit

Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases. The Company's main product is PROTAC, which degrades and removes disease-causing proteins.

TypePublic
HQNew Haven, CT, US
Websitearvinas.com

Latest Updates

Employees (est.) (Dec 2019)133(+30%)
Job Openings40
Revenue (FY, 2020)$21.8 M(-49%)
Share Price (Sept 2021)$94.2
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Arvinas

Timothy Shannon

Timothy Shannon

Chairman of the Board
John G. Houston

John G. Houston

President and Chief Executive Officer
Matthew Batters

Matthew Batters

General Counsel
Angela M. Cacace

Angela M. Cacace

Vice President of Neuroscience and Platform Biology
Sean Cassidy

Sean Cassidy

Chief Financial Officer
John A. Grosso

John A. Grosso

Vice President of Chemistry, Manufacturing, and Controls
Show more

Arvinas Office Locations

Arvinas has an office in New Haven
New Haven, CT, US (HQ)
5 Science Park
Show all (1)

Arvinas Financials and Metrics

Arvinas Revenue

Arvinas's revenue was reported to be $21.8 m in FY, 2020
USD

Revenue (Q1, 2021)

5.5m

Net income (Q1, 2021)

(41.0m)

EBIT (Q1, 2021)

(41.6m)

Market capitalization (23-Sept-2021)

4.6b

Closing stock price (23-Sept-2021)

94.2

Cash (31-Mar-2021)

346.1m

EV

4.3b
Arvinas's current market capitalization is $4.6 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.7m7.6m14.3m43.0m21.8m

Revenue growth, %

14%

General and administrative expense

3.2m3.5m12.9m27.3m38.3m

R&D expense

19.9m28.8m45.2m67.2m108.4m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.7m3.4m4.0m4.0m30.1m6.2m5.7m7.6m5.5m

General and administrative expense

857.3k4.3m5.6m6.4m8.0m7.9m8.8m9.3m12.3m

R&D expense

7.2m13.1m14.2m16.0m16.6m21.7m23.4m30.0m34.9m

Operating expense total

8.1m17.4m19.8m22.4m24.5m29.7m32.2m39.3m47.2m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

5.1m30.9m3.2m9.2m588.4m

Accounts Receivable

25.0m2.8m6.3m1.0m

Prepaid Expenses

1.4m316.9k2.8m3.7m6.1m

Current Assets

37.3m65.5m195.7m290.9m703.1m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

6.2m28.8m11.3m12.1m36.1m21.6m89.0m346.1m

Accounts Receivable

2.5m1.4m59.3k3.9m3.6m2.4m5.2m

Prepaid Expenses

3.5m2.3m2.7m4.0m3.5m3.3m3.5m8.2m

Current Assets

95.5m179.7m163.3m199.7m270.2m249.6m258.0m664.7m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(14.4m)(24.0m)(41.5m)(70.3m)(119.3m)

Depreciation and Amortization

436.3k347.4k706.0k1.6m3.2m

Accounts Payable

1.2m(969.5k)2.0m1.6m2.0m

Cash From Operating Activities

(19.4m)5.1m(16.1m)(40.6m)(89.8m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(19.3m)(25.4m)(14.4m)(31.6m)(49.2m)(21.7m)(47.0m)(77.8m)(41.0m)

Depreciation and Amortization

246.4k483.1k246.2k556.6k1.0m617.5k1.3m2.1m1.1m

Accounts Payable

(648.0k)704.2k(1.7m)(1.4m)(619.0k)(1.9m)(2.3m)(246.7k)1.8m

Cash From Operating Activities

(23.0m)(3.9m)(12.7m)(26.3m)(24.4m)(16.9m)(38.4m)(60.7m)(39.0m)
USDFY, 2016

Financial Leverage

-1.2 x
Show all financial metrics

Arvinas Acquisitions / Subsidiaries

Company NameDateDeal Size
Arvinas Androgen Receptor
Arvinas BRD4
Arvinas Estrogen Receptor
Arvinas Winchester

Arvinas Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Arvinas Online and Social Media Presence

Embed Graph

Arvinas News and Updates

Arvinas Inc Ranked Among Today’s Top Shorts As Chinese Property Giant Evergrande Teeters On The Edge Of Defaulting On $300B Worth Of Debt

The indices ticked up with the Dow Jones rising 142 points or 0.4%, the S&P 500 gaining 0.4%, and the Nasdaq bouncing 0.5%. Find opportunities in today's market with the best short plays from Q.ai's deep learning algorithms.

Arvinas Inc Ranked Among Today’s Top Shorts As Investors Await Upcoming Federal Reserve Meetings

The Dow Jones and S&P 500 rose about 0.3%, while the Nasdaq climbed 0.4%. Make the most of this market with today's best short plays from Q.ai's deep learning algorithms.

Arvinas Inc Ranked Among Today’s Top Shorts Amid Lower-Than-Expected New Jobs

The Dow Jones fell about 68 points or 0.2%, and the S&P 500 and the Nasdaq dipped about 0.1% each. Find opportunities in today's market with the best short plays from Q.ai's deep learning algorithms.

Arvinas Inc Ranked Among Today’s Top Shorts Amid Pandemic-Era Low Jobless Claims

The Dow Jones ticked down 14 points, the S&P 500 was flat, and the Nasdaq rose about 0.2%. Find opportunities in today's market with the best short plays from Q.ai's artificial inteligence.

Arvinas Inc Ranked Among Today’s Top Shorts

The Dow Jones rose 10 points, while both the S&P 500 and Nasdaq also saw mild gains. Find opportunities in today's market with the best short plays from Q.ai's deep learning algorithms.

Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Show more

Arvinas Blogs

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven Content Import Mon, 06/07/2021 - 17:20 Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven June 7, 2021…

Arvinas to Present at the UBS Global Healthcare Virtual Conference

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven

– Company to lease approximately 160,000-square-feet to allow continued growth and expansion of operations – NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021 Content Import Mon, 04/05/2021 - 16:30 Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021 April 5, 2021 at 4…

Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief

Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares

NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced that the underwriters of its previously announced
Show more

Arvinas Frequently Asked Questions

  • Who are Arvinas key executives?

    Arvinas's key executives are Timothy Shannon, John G. Houston and Matthew Batters.

  • How many employees does Arvinas have?

    Arvinas has 133 employees.

  • What is Arvinas revenue?

    Latest Arvinas annual revenue is $21.8 m.

  • What is Arvinas revenue per employee?

    Latest Arvinas revenue per employee is $163.9 k.

  • Who are Arvinas competitors?

    Competitors of Arvinas include Lyell, Foghorn Therapeutics and OnQuality Pharmaceuticals.

  • Where is Arvinas headquarters?

    Arvinas headquarters is located at 5 Science Park, New Haven.

  • Where are Arvinas offices?

    Arvinas has an office in New Haven.

  • How many offices does Arvinas have?

    Arvinas has 1 office.